Sunshine Biopharma Inc

Sunshine Biopharma Inc(SBFM)股票分析

$2.705

-0.083 (-3.05%)收盤時

Loading chart…
最高
2.850
開盤
2.730
成交量加權均價
2.74
成交量
36.20K
市值
8.33M
最低
2.680
成交金額
99.37K
企業價值/稅息折舊攤銷前利潤(TTM)
1.46

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

AI 分析 of Sunshine Biopharma Inc (SBFM)

賣出

Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.

估值指標

Sunshine Biopharma Inc(SBFM)目前預期本益比為 0.00,5 年平均預期本益比為 -1.93。

預期本益比

合理
5 年均值 P/E
-1.93
目前P/E
0.00
高估
0.49
低估
-4.34

預期 EV/EBITDA

嚴重高估
5 年均值 EV/EBITDA
0.10
目前EV/EBITDA
1.46
高估
0.45
低估
-0.25

預期股價營收比

合理
5 年均值 P/S
0.16
目前P/S
0.05
高估
0.39
低估
-0.07

Alphio AI 對 SBFM 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SBFM

$1.99

情境價格

基

基準

基準 · 50%SBFM

$1.88

情境價格

悲

悲觀

悲觀 · 25%SBFM

$1.86

情境價格

持有 SBFM 的大戶

L

L1 Capital Pty. Limited

+ 持有SBFM

+9.12%

3個月報酬率

事件時間軸

2026-10-08 (ET)

09:00:00

Sunshine Biopharma Prices Public Offering at $6 Million

2026-09-24 (ET)

09:30:00

Sunshine Biopharma Launches 4mg and 8mg Ondansetron Generics in Canada

2026-09-16 (ET)

09:30:00

Sunshine Biopharma Advances Coronavirus Drug Candidate into IND Studies

2026-08-31 (ET)

09:30:00

Sunshine Biopharma Receives Approval for Atenolol Tablets

2026-08-28 (ET)

16:30:00

Sunshine Biopharma Files to Sell 24.48M Shares of Common Stock

資訊

SBFM 常見問題 —— 由 Alphio AI 解答

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易